|Bid||271.85 x 800|
|Ask||281.97 x 900|
|Day's range||276.37 - 281.89|
|52-week range||119.01 - 319.19|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||81.03|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.
Abiomed (NASDAQ: ABMD) struggled in 2019, but the stock has risen more than 62% so far this year. Abiomed's devices all have to do with the circulatory system, including the world's smallest heart pump, the Impella. Since the company acquired the Impella technology by buying German company Impella CardioSystems in 2005, Abiomed's revenue has risen every year.